About one-third of head and neck squamous cell cancer (HNSCC) survivors who have undergone radiation therapy (RT) are ...

Low-dose computed tomography is more sensitive than chest radiography in diagnosing lung metastases of second primary lung cancer in HNSCC survivors.

First-line treatment with a Keytruda combo had an overall survival of 17.6 months in some with recurrent/metastatic head and ...

Adding perioperative pembrolizumab to standard care can improve EFS in locally advanced head and neck cancer, data suggest.

Adding pembrolizumab before and after surgery reduced recurrence and improved response in patients with locally advanced head ...

Head and neck cancers — including oral ... These cancers begin in the squamous cells that line the moist surfaces of the mouth, nose and throat. Depending on the location and stage, symptoms ...

DelveInsight’s Head and Neck Cancer pipeline report depicts a robust space with 80+ active players working to develop 100+ ...

ADRX-0706 has received FDA fast track designation for the treatment of metastatic or locally advanced squamous cell cervical ...

Patients with locally advanced head and neck cancer who received the immune checkpoint inhibitor pembrolizumab before, during and after standard-of-care surgery had longer event-free survival without ...

A new study published in Engineering has identified enolase 2 (ENO2) as a key factor in the lymphatic metastasis of head and neck squamous cell ...

Immutep's eftilagimod shows a 17.6-month survival benefit in head and neck cancer. Find out how and why IMMP is continuing to ...